Show
Sort by
-
Targeted therapy of TERT-rearranged neuroblastoma with BET bromodomain inhibitor and proteasome inhibitor combination therapy
-
- Journal Article
- A1
- open access
Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)
-
Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients
-
- Journal Article
- A1
- open access
Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients
-
Identification of novel, rare markers for poor survival in high-risk neuroblastoma patients by merging and reanalysing existing datasets
-
Genomic amplifications and distal 6q loss are novel markers for poor survival in high-risk neuroblastoma patients
-
Distal chromosome 6q deletion defines a group of ultra-high risk neuroblastoma patients
-
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
-
- Journal Article
- A1
- open access
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
-
Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma
-
Genome-wide methylation analysis unravels differential DNA methylation patterns between (prognostic) neuroblastoma patient subgroups
-
Emergence of new ALK mutations at relapse of neuroblastoma
-
- Journal Article
- A1
- open access
Focal DNA copy number changes in neuroblastoma target MYCN regulated genes
-
A multilocus technique for risk evaluation of patients with neuroblastoma
-
Aberrant methylation of candidate tumor suppressor genes in neuroblastoma
-
Chromosome 3p microsatellite allelotyping in neuroblastoma: a report on the technical hurdles
-
Identification of 2 putative critical segments of 17q gain in neuroblastoma through integrative genomics
-
ArrayCGH-based classification of neuroblastoma into genomic subgroups
-
ArrayCGH based classification of neuroblastoma into genomic subgroups
-
No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas
-
- Journal Article
- A1
- open access
No evidence for involvement of SDHD in neuroblastoma pathogenesis